Bibliography
- CARDEN DL, GRANGER DN: Pathophysiology of ischaemia-reperfusion injury. J. Pathol (2000) 190:255–266.
- CALABRESI L, GOMARASCHI M, FRANCESCHINI G: Endothelial protection by high-density lipoproteins: from bench to bedside. Arteriosclec Thromb. Vasc. Biol. (2003) 23:1724–1731.
- STANGL V, BAUMANN G, STANGL K, FELIX SB: Negative inotropic mediators released from the heart after myocardial ischaemia-reperfusion. Cardiovasc. Res. (2002) 53:12–30.
- IRWIN MW, MAK S, MANN DL et al.: Tissue expression and immunolocalization of tumor necrosis factor-a in postinfarction dysfunctional myocardium. Circulation (1999) 99:1492–1498.
- MELDRUM DR: Tumor necrosis factor in the heart. Ain. Physiol (1998) 274:R577–R595.
- LEFER DJ, GRANGER DN: Oxidative stress and cardiac disease. Am. J. Med. (2000) 109:315–323.
- CALABRESI L, ROSSONI G, GOMARASCHI M et al.: High-density lipoproteins protect isolated rat hearts from ischemia-reperfusion injury by reducing cardiac tumor necrosis factor-a content and enhancing prostaglandin release. Circulation Research (2003) 92:330–337.
- ••First demonstration of cardioprotection byplasma-derived HDL.
- BOWRY VW, STANLEY KK, STOCKER R: High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. Proc. Nat. Acad. Sci. USA (1992) 89:10316–10320.
- MACKNESS MI, DURRINGTON PN, MACKNESS B: How high-density lipoprotein protects against the effects of lipid perwddation. Can: Opin. Lipidol (2000) 11:383–388.
- ROSSONI G, GOMARASCHI M, BERTI F et al.: Synthetic high-density lipoproteins exert cardioprotective effects in myocardial ischemia/reperfusion injury. Pharmacol Exp. Therap. (2004) 308:79–84.
- ••First demonstration of cardioprotection bysHDL.
- SIRTORI CR, CALABRESI L, FRANCESCHINI G: Recombinant apolipoproteins for the treatment of vascular diseases. Atherosclerosis (1999) 142:29–40.
- NISSEN SE, TSUNODA T, TUZCU EM et al.: Effect of recombinant apoA-Im on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA (2003) 290:2292–2300.
- ••First demonstration of regression ofatherosclerosis in coronary patients by sHDL.